Rapamycin in aging and disease: maximizing efficacy while minimizing side effects

Experimental geroscience has identified rapamycin as a top candidate for promoting healthy aging and longevity in mammals. As multiple independent studies have successfully reproduced the lifespan and healthspan promoting effects of rapamycin, the focus has shifted to possible translational use. Whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Simon C., Kaeberlein, Matt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216691/
https://www.ncbi.nlm.nih.gov/pubmed/27384492
http://dx.doi.org/10.18632/oncotarget.10381
_version_ 1782491960933613568
author Johnson, Simon C.
Kaeberlein, Matt
author_facet Johnson, Simon C.
Kaeberlein, Matt
author_sort Johnson, Simon C.
collection PubMed
description Experimental geroscience has identified rapamycin as a top candidate for promoting healthy aging and longevity in mammals. As multiple independent studies have successfully reproduced the lifespan and healthspan promoting effects of rapamycin, the focus has shifted to possible translational use. While a promising compound, clinical use of rapamycin is limited by concerns of side effects associated with the drug. Studies aimed at defining optimal dosage regimen, delivery route, and formulation will allow for benefits to be maximized while reducing side effects.
format Online
Article
Text
id pubmed-5216691
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-52166912017-01-15 Rapamycin in aging and disease: maximizing efficacy while minimizing side effects Johnson, Simon C. Kaeberlein, Matt Oncotarget Research Perspective Experimental geroscience has identified rapamycin as a top candidate for promoting healthy aging and longevity in mammals. As multiple independent studies have successfully reproduced the lifespan and healthspan promoting effects of rapamycin, the focus has shifted to possible translational use. While a promising compound, clinical use of rapamycin is limited by concerns of side effects associated with the drug. Studies aimed at defining optimal dosage regimen, delivery route, and formulation will allow for benefits to be maximized while reducing side effects. Impact Journals LLC 2016-07-01 /pmc/articles/PMC5216691/ /pubmed/27384492 http://dx.doi.org/10.18632/oncotarget.10381 Text en Copyright: © 2016 Johnson and Kaeberlein http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Perspective
Johnson, Simon C.
Kaeberlein, Matt
Rapamycin in aging and disease: maximizing efficacy while minimizing side effects
title Rapamycin in aging and disease: maximizing efficacy while minimizing side effects
title_full Rapamycin in aging and disease: maximizing efficacy while minimizing side effects
title_fullStr Rapamycin in aging and disease: maximizing efficacy while minimizing side effects
title_full_unstemmed Rapamycin in aging and disease: maximizing efficacy while minimizing side effects
title_short Rapamycin in aging and disease: maximizing efficacy while minimizing side effects
title_sort rapamycin in aging and disease: maximizing efficacy while minimizing side effects
topic Research Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216691/
https://www.ncbi.nlm.nih.gov/pubmed/27384492
http://dx.doi.org/10.18632/oncotarget.10381
work_keys_str_mv AT johnsonsimonc rapamycininaginganddiseasemaximizingefficacywhileminimizingsideeffects
AT kaeberleinmatt rapamycininaginganddiseasemaximizingefficacywhileminimizingsideeffects

Ejemplares similares